

Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome

Christoph Engel, Markus Loeffler, Verena Steinke, Nils Rahner, Elke Holinski-Feder, Wolfgang Dietmaier, Hans K. Schackert, Heike Goergens, Magnus von Knebel Doeberitz, Timm O. Goecke, Wolff Schmiegell, Reinhard Buettner, Gabriela Moeslein, Tom G.W. Letteboer, Encarna Gómez García, Frederik J. Hes, Nicoline Hoogerbrugge, Fred H. Menko, Theo A.M. van Os, Rolf H. Sijmons, Anja Wagner, Irma Kluijdt, Peter Propping, and Hans F.A. Vasen

Author affiliations appear at the end of this article.

Submitted April 1, 2012; accepted September 5, 2012; published online ahead of print at www.jco.org on October 22, 2012.

Written on behalf of the German Hereditary Nonpolyposis Colorectal Cancer Consortium and the Netherlands Foundation for the Detection of Hereditary Tumours.

Supported by the Deutsche Krebshilfe (German Cancer Aid).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Christoph Engel, MD, Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16-18, 04107 Leipzig, Germany; e-mail: christoph.engel@imise.uni-leipzig.de.

© 2012 by American Society of Clinical Oncology

0732-183X/12/3035-4409/\$20.00

DOI: 10.1200/JCO.2012.43.2278

A B S T R A C T

Purpose

Patients with Lynch syndrome are at high risk for colon and endometrial cancer, but also at an elevated risk for other less common cancers. The purpose of this retrospective cohort study was to provide risk estimates for these less common cancers in proven carriers of pathogenic mutations in the mismatch repair (MMR) genes *MLH1*, *MSH2*, and *MSH6*.

Patients and Methods

Data were pooled from the German and Dutch national Lynch syndrome registries. Seven different cancer types were analyzed: stomach, small bowel, urinary bladder, other urothelial, breast, ovarian, and prostate cancer. Age-, sex- and MMR gene-specific cumulative risks (CRs) were calculated using the Kaplan-Meier method. Sex-specific incidence rates were compared with general population incidence rates by calculating standardized incidence ratios (SIRs). Multivariate Cox regression analysis was used to estimate the impact of sex and mutated gene on cancer risk.

Results

The cohort comprised 2,118 MMR gene mutation carriers (*MLH1*, $n = 806$; *MSH2*, $n = 1,004$; *MSH6*, $n = 308$). All cancers were significantly more frequent than in the general population. The highest risks were found for male small bowel cancer (SIR, 251; 95% CI, 177 to 346; CR at 70 years, 12.0; 95% CI, 5.7 to 18.2). Breast cancer showed an SIR of 1.9 (95% CI, 1.4 to 2.4) and a CR of 14.4 (95% CI, 9.5 to 19.3). *MSH2* mutation carriers had a considerably higher risk of developing urothelial cancer than *MLH1* or *MSH6* carriers.

Conclusion

The sex- and gene-specific differences of less common cancer risks should be taken into account in cancer surveillance and prevention programs for patients with Lynch syndrome.

J Clin Oncol 30:4409-4415. © 2012 by American Society of Clinical Oncology

INTRODUCTION

Lynch syndrome (LS), often also termed hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal-dominant inherited disorder caused by germline mutations in genes of the DNA mismatch repair (MMR) system.¹ Patients affected by this condition are at a considerably increased risk of developing colorectal and endometrial cancer. In addition, other cancers such as carcinomas of the stomach, small bowel, ovaries, biliary tract, urinary tract, and brain and sebaceous tumors are observed more frequently than in the general population.² Reliable estimates of age-, gene-, and sex-specific risks for these less common cancers are important for the design of appropriate surveillance and prevention programs. Specific surveillance measures

may be narrowed down and tailored according to age, sex, and endangered target organ. Moreover, cancer risks may be considerably different according to the mutated MMR gene, thus making specific recommendations necessary. Several studies have been published giving risk estimates for a variety of extra-colonic, extra-endometrial cancers, including a large collaborative study combining data of 6,041 proven or probable *MLH1* and *MSH2* mutation carriers from four LS registries.³⁻¹³

In this study we aimed to estimate the risks of less common cancers in patients with a proven mutation in the MMR genes *MLH1*, *MSH2*, or *MSH6*. We were particularly interested in analyzing the risks by sex and mutated MMR gene. Furthermore, we sought to compare the risk estimates with those from the general population. To achieve a sufficient

number of patients for the analysis, the study was conducted as a joint project of two registries from Germany and the Netherlands.

PATIENTS AND METHODS

For the present analysis, we pooled data from the registry of the German HNPCC Consortium and the registry of the Netherlands Foundation for the Detection of Hereditary Tumors. The German registry has been collecting data since 1995 and the Dutch registry since 1986. Details about the two registries are described elsewhere.¹³⁻¹⁶ In these two registries, families and patients are ascertained through clinical criteria based on familial clustering of colorectal cancer or early onset of cancer (Amsterdam criteria and Bethesda guidelines).¹⁷⁻²⁰ Comprehensive data on the tumor spectrum and the age of diagnosis were collected for all members of the families. The index patients of the families underwent a standardized process of genetic counseling, tumor tissue analysis for microsatellite instability and/or immunohistochemical staining of MMR proteins, and mutation analysis of the four major MMR genes *MLH1*, *MHS2*, *MSH6*, and *PMS2*. *PMS2* mutations were too rare to be included in the present analysis. All participants gave their written informed consent at study inclusion. The ethics committees of each participating institution approved the study. A central data quality management process was implemented to ensure high data quality (automated checks for completeness, plausibility, and consistency), raising queries in case of errors.

The following information on all mutation carriers were queried from the two registries: sex, affected MMR gene, age at last follow-up, and year of birth. For all these individuals, a complete list was generated with all invasive cancer events, including type of cancer and age at diagnosis (total number of noncolonic nonendometrial cancers was 389). The present analysis was restricted only to proven mutation carriers. So-called probable mutation carriers (ie, relatives of a mutation carrier with unknown mutation status but with a history of colorectal or endometrial cancer) were not included to minimize biases attributable to potential phenocopies. The group of mutation carriers comprised the index patients of the families and all relatives who were tested positive for a pathogenic mutation. Ninety percent of cancer diagnoses were confirmed by medical or pathology reports.

Statistical Analysis

Age-dependent cumulative risks (CR) and their 95% CIs were estimated using the Kaplan-Meier product-limit method. The log-rank test was used to compare risks between groups (defined by the mutated MMR gene or sex). Multivariate Cox regression modeling was used to estimate the effect of sex (only for cancers affecting both sexes) and mutated MMR gene, adjusted by registry (Germany v Netherlands) and year of birth to account for potential birth cohort effects. Results were presented as hazard ratios (HR) and their 95% CIs. For each individual, the time under risk reached from birth until death, last follow-up, or the cancer of interest, whichever came first. For comparison of risks in mutation carriers with those in the general population, standardized incidence ratios (SIRs) were calculated by dividing the number of observed cases by the number of expected cases. The number of expected cases was calculated by multiplying the age-, sex-, and annual calendar year-specific incidence rates for the general population with the corresponding person-years obtained from the study population. Ninety-five percent CIs were calculated assuming a Poisson distribution. Expected cancer numbers were calculated separately for the Dutch and German sample using their country-specific population incidence rates. Incidence rates for the German general population were obtained from the Saarland Cancer Registry and for the Dutch general population from the Netherlands Cancer Registry. The earliest calendar year for which incidence data were available was 1970 for Germany and 1989 for the Netherlands. For earlier years, we used linear extrapolation of incidences from the known calendar years.

All reported *P* values are two-sided. *P* values <.05 were considered statistically significant. IBM SPSS 20.0.0.1 (SPSS, Chicago, IL) was used for all data analyses.

Table 1. Characteristics of the Study Population

Characteristic	Total		Germany		Netherlands	
	No.	%	No.	%	No.	%
All individuals, n	2,118		1,257		861	
Sex	1,011	47.7	657	52.3	354	41.1
Male	1,107	52.3	600	47.7	507	58.9
Female						
Year of birth						
Median	1958		1959		1956	
Range	1911-1993		1911-1993		1916-1989	
MMR gene						
<i>MLH1</i>	806	38.1	483	38.4	323	37.5
<i>MSH2</i>	1,004	47.4	650	51.7	354	41.1
<i>MSH6</i>	308	14.5	124	9.9	184	21.4
Affected with cancer						
Colon or rectum	1,050	49.6	824	65.6	226	26.2
Endometrium	177	16.0	102	17.0	75	14.8
Stomach	33	1.6	29	2.3	4	0.5
Small bowel	54	2.5	38	3.0	16	1.9
Urinary bladder	31	1.5	22	1.8	9	1.0
Other urothelium	45	2.1	31	2.5	14	1.6
Breast	50	4.5	26	4.3	24	4.7
Ovary	49	4.4	32	5.3	17	3.4
Prostate	17	1.7	12	2.0	4	1.1
Other cancers*	110	5.5	76	6.0	34	3.9

*CNS, skin, pancreas, kidney, leukemia, lung, gallbladder, thyroid.

RESULTS

The study cohort comprised a total of 2,118 individuals with a proven pathogenic mutation in *MLH1*, *MSH2*, or *MSH6*. Table 1 shows the basic characteristics. The proportion of male mutation carriers was significantly higher in the German than in the Dutch cohort (52.3% v 41.1%, respectively; *P* < .001), whereas the age structure was similar (median year of birth, 1957; *P* = .34). The distribution of the mutated gene was also significantly different between the two registries (*P* < .001). *MSH6* mutation carriers were more frequent in the Dutch than in the German cohort (21.4% v 9.9%, respectively). The frequency of patients with colorectal cancer was considerably higher in the German than in the Dutch cohort (65.6% v 26.2%).

Figures 1 and 2 show the age-dependent cumulative risks for the seven cancer types compared by gene and sex (univariate comparison). Table 2 gives information about mean ages at diagnosis, cumulative lifetime risks at 70 years, and SIRs with regard to the general population. Table 3 summarizes the results of multivariate modeling of sex and mutated gene, adjusted for registry and year of birth.

Among the seven less common cancer types considered in our analysis, small bowel and ovarian cancer showed the earliest mean ages at diagnosis (mean, 46 years for small bowel and 44 years for ovarian cancer). Only cancers of the stomach, small bowel, and the ovaries were observed before the age of 30 years. The highest cumulative lifetime risks were observed for breast cancer (14.4%; 95% CI, 9.5% to 19.3%) and small bowel cancer in men (12.0%; 95% CI, 5.7% to 18.2%). Stomach cancer in female mutation carriers had the lowest lifetime risk (2.6%; 95% CI, 1.1% to 4.1%). Clearly significant risk differences between male and female mutations carriers could only be




Fig 1. Age-dependent cumulative risks for (A, B) gastric, (C, D) small bowel, (E, F) urinary bladder, and (G, H) other urothelial cancers, compared by sex (left panels) and by mutated gene (right panels).




Fig 2. Age-dependent cumulative risks for (A) breast, (B) ovarian and (C) prostate cancer, compared by mutated gene.

observed for small bowel cancer, with a hazard ratio (HR) for male carriers of 2.52 (95% CI, 1.41 to 4.50). Male carriers had a two-fold increased risk for gastric cancer compared with women (HR = 2.00; 95% CI, 0.98 to 4.10); however, this difference was borderline nonsignificant in the multivariate analysis ($P = .058$). Cancers of the urinary tract showed no significant risk differences by sex in the multivariate analysis, even though the risk was estimated to be higher for male carriers.

Risk differences between *MLH1*, *MSH2*, and *MSH6* mutation carriers were found for gastric and small bowel cancer, cancers of the urinary tract (urinary bladder and other urothelial cancers), ovarian cancer, and prostate cancer. For stomach and small bowel cancer, *MLH1* and *MSH2* mutation carriers had similar cumulative risks; however, *MSH6* carriers showed a significantly decreased risk com-

Table 2. Mean Ages at Diagnosis, Cumulative Lifetime Risks, and SIRs Compared With the General Population

Organ	Male		Female	
	%	95% CI	%	95% CI
Age at diagnosis, years				
Stomach				
Median	51		49	
Range	28-78		40-58	
Small bowel				
Median	46		46	
Range	25-73		23-71	
Urinary bladder				
Median	53		55	
Range	34-75		43-74	
Other urothelium				
Median	52		57	
Range	32-73		41-74	
Breast				
Median	—		52	
Range	—		30-76	
Ovary				
Median	—		44	
Range	—		26-58	
Prostate				
Median	59		—	
Range	50-74		—	
Cumulative risk at 70 years				
Stomach	6.7	3.1 to 10.3	2.6	1.1 to 4.1
Small bowel	12.0	5.7 to 18.2	3.9	1.2 to 6.5
Urinary bladder	5.5	2.7 to 8.3	3.5	1.4 to 5.5
Other urothelium	9.4	4.6 to 14.1	6.0	2.9 to 9.1
Breast	—	—	14.4	9.5 to 19.3
Ovary	—	—	8.0	5.8 to 10.3
Prostate	9.1	4.4 to 13.8	—	—
SIR				
Stomach	9.8	6.0 to 14.9	7.2	3.7 to 12.6
Small bowel	250.9	176.7 to 345.9	112.2	65.4 to 179.7
Urinary bladder	8.5	5.0 to 13.5	16.2	8.6 to 27.8
Other urothelium	100.4	65.0 to 148.2	121.8	74.4 to 188.2
Breast	—	—	1.9	1.4 to 2.4
Ovary	—	—	13.6	10.0 to 17.9
Prostate	2.5	1.4 to 4.0	—	—

Abbreviation: SIR, standardized incidence ratio.

pared with *MLH1* carriers. Regarding urothelial cancer, *MSH2* mutation carriers had a considerably higher risk compared with *MLH1* and *MSH6* mutation carriers. A similar gene-dependent risk pattern was found for prostate cancer, although quantitative risk estimation was not possible in the multivariate analysis. A different pattern was found for ovarian cancer, with comparable risks between *MSH2* and *MSH6* mutation carriers and a reduced risk for *MLH1* mutation carriers.

All seven cancer types were significantly more frequent and occurred earlier than expected in the general population (Table 2). This was even the case for breast cancer, with an SIR of 1.9 (95% CI, 1.4 to 2.4) and a mean age at diagnosis of 52 years (range, 30 to 76 years). The highest SIRs were found for small bowel cancer and urothelial cancer (SIRs between 100 and 251). There was no significant heterogeneity in cancer risks between the German and Dutch sample except for stomach cancer, for which the risk was significantly lower in the Dutch sample (HR = 0.24; 95% CI, 0.08 to 0.67; $P = .007$).

Table 3. Association of Sex and Mutated Gene on the Risks of Less Common Cancers: Results of Multivariate Cox Regression Modeling

Variable	Hazard Ratio	95% CI	P
Stomach			
Male sex	2.00	0.98 to 4.10	.058
MMR gene			
<i>MSH2</i>	1.03	0.52 to 2.06	.936
<i>MSH6</i>	*	*	*
Small bowel			
Male sex	2.52	1.41 to 4.50	.002
MMR gene			
<i>MSH2</i>	1.00	0.58 to 1.73	.993
<i>MSH6</i>	0.11	0.02 to 0.83	.032
Urinary bladder			
Male sex	1.73	0.84 to 3.54	.137
MMR gene			
<i>MSH2</i>	5.42	1.89 to 15.56	.002
<i>MSH6</i>	0.57	0.06 to 5.18	.620
Other urothelium			
Male sex	1.54	0.85 to 2.78	.156
MMR gene			
<i>MSH2</i>	8.27	2.95 to 23.19	< .001
<i>MSH6</i>	1.05	0.19 to 5.78	.957
Breast			
MMR gene			
<i>MSH2</i>	0.92	0.50 to 1.69	.917
<i>MSH6</i>	0.77	0.34 to 1.76	.539
Ovary			
MMR gene			
<i>MSH2</i>	2.09	1.04 to 4.21	.040
<i>MSH6</i>	2.59	1.11 to 6.05	.027
Prostate			
MMR gene			
<i>MSH2</i>	*	*	*
<i>MSH6</i>	*	*	*

NOTE. Female sex and *MLH1* gene were reference categories adjusted for registry (Germany v Netherlands) and year of birth.
Abbreviation: MMR, mismatch repair.

*No estimation possible.

of less common cancer risks and on the other hand to an overestimation of colorectal and endometrial cancer risks.

Gastric cancer risk was significantly increased compared with that of the general population (SIR 9.8 for male and 7.2 for female mutation carriers). We also found that gastric cancer risk was considerably lower in the Dutch than in the German study cohort (HR = 0.24). This explains why a separate Dutch study reports only SIRs of 3.8 for male and 2.7 for female individuals.¹⁰ However, the reason for this risk difference remains unclear, especially because age-standardized incidence rates are not largely different between the German and Dutch general population.²² Aarnio et al² reported an SIR of 6.9 in 360 proven and obligate mutation carriers, which is more in agreement with our present finding. The cumulative lifetime risks for gastric cancer in *MLH1* and *MSH2* carriers in our study were also in concordance with the figures reported by Watson et al.⁹ Also in agreement with the study by Watson et al,⁹ we did not detect a significant risk difference for gastric cancer between *MLH1* and *MSH2* mutation carriers. In contrast to the study of Watson et al,⁹ we found a relevant difference in gastric cancer risk between male and female individuals (HR = 2.00), which was significant in the univariate analysis and nearly significant in the multivariate analysis ($P = .02$ and $P = .058$, respectively). Barrow et al¹² also report significant differences between male and female patients.

Small bowel cancer showed the highest risk increase compared with the general population (SIR of 251 for male and 112 for female mutation carriers). Cumulative risk figures at age 70 years are higher than reported by others.^{9,12,23} Male carriers had a significantly higher risk than female carriers (HR = 2.5). Small bowel cancer risk was significantly lower in *MSH6* mutation carriers compared with *MLH1* and *MSH2* mutation carriers.

Bladder cancer was significantly more frequent than expected in the general population (SIR of 8.5 for male and 16.2 for female mutation carriers). *MSH2* mutation carriers had a considerably increased risk to develop bladder cancer compared with *MLH1* and *MSH6* carriers. This is in accordance with two other studies, which also found significantly higher risks in *MSH2* mutation carriers.^{7,9} Our result supports the observation that bladder cancer is part of the tumor spectrum of LS.

The risk for ovarian cancer was approximately 14 times higher than in the general population, which is consistent with data from Aarnio et al.² Interestingly, *MSH2* and *MSH6* carriers had significantly higher risks than *MLH1* carriers (HR = 2.1 for *MSH2* and 2.6 for *MSH6*, respectively). Watson et al⁹ have reported previously substantially higher risks for carriers of *MSH2* mutations than for *MLH1*-mutation carriers.

Our analysis suggests that breast cancer risk is significantly elevated compared with the general population (SIR of 1.9). There was no significant heterogeneity for breast cancer risk between the German and the Dutch registry. There were also no differences in the risks between *MLH1*, *MSH2*, and *MSH6*. Most other studies did not show a significantly higher risk for breast cancer.^{2,9} However, Scott et al⁶ reported a significant overrepresentation of breast cancers in *MSH2* mutation carriers (SIR = 14.77). The lifetime risk for breast cancer was approximately 14% in our analysis, which is considerably higher than reported in the study by Watson et al⁹ (5.4%). In the light of these conflicting results regarding breast cancer risks, larger studies are required to further investigate whether breast cancer is part of the tumor spectrum of LS.

DISCUSSION

In this retrospective cohort study, we investigated the risks of less common cancers in patients with LS. We were particularly interested in describing risk differences by sex and mutated MMR gene (*MLH1*, *MSH2*, and *MSH6*). Colorectal cancer and endometrial cancer were not included in this analysis because patients were preferentially ascertained on the basis of the presence of these cancers in their families. Therefore, in retrospective studies, the risks for these cancers are likely to be largely overestimated if the analysis does not account for ascertainment bias.²¹ Furthermore, we restricted our analysis to individuals with a proven mutation. Many other studies have also included family members with unknown mutation status. These members were assumed to have a mutation if they already had been diagnosed with colorectal or endometrial cancer (so-called probable mutation carriers). However, it cannot be excluded that some of these individuals had only sporadic cancer. Consequently, the inclusion of such individuals into the analysis may lead on the one hand to an underestimation

The risk of prostate cancer was significantly increased compared with that of the general population (SIR of 2.5). The highest risk was found in carriers of *MSH2* mutations. Grindedal et al⁵ recently reported an even higher risk increase for prostate cancer (SIR of 5.9) in 106 mutation carriers. They reported that prostate cancer was only observed in carriers of *MSH2*, *MSH6*, and *PMS2* mutations but not in those with *MLH1* mutations.

Pancreatic cancer and other types of cancer could not be included in our analysis because the number of events was too small to yield conclusive risk estimates. However, other studies suggest that the risk of pancreatic cancer is increased in families with LS compared with the general population.⁴

In our study, male patients with LS generally had higher risks for gastric, small bowel, and urothelial cancer than female patients. These risk differences might be explained at least in part by different environmental exposures or lifestyles (eg, regarding smoking habits, alcohol consumption, or dietary factors).²⁴ Recently, studies have been published demonstrating an association between smoking or body mass index and colorectal adenoma or cancer risk.²⁵⁻²⁸ However, studies addressing the possible association between these factors and the less common cancers in LS are not yet available.

Our study confirms that less common cancers show organ-specific risk differences with regard to the mutated MMR gene. The reason for this gene and organ specificity is yet not well understood. The MMR system consists of different MMR proteins interacting with each other to detect and to repair DNA mismatches. It has been proposed that likely several distinct mechanisms contribute to the observed of tissue specificity (eg, cell type-specific mutator targets, specific apoptotic pathways, interactions between the MMR system and environmental factors, and others).²⁹

Some limitations of our study should be addressed. *PMS2* mutation carriers were not included in this study, because their number was far too small to obtain reasonable risk estimates. Another limitation is that retrospective analyses may lead to an overestimation of risks for those types of cancer, which were the basis for selection (ascertainment bias).²¹ However, most families were identified by clustering or early onset of colorectal or endometrial cancer. Therefore, we believe that risk estimates for the less common noncolonic nonendometrial cancers should not be severely affected. However, the risk estimates from our study may not apply to mutation carriers who were ascertained under different conditions and should therefore be interpreted with caution. To overcome the specific problem of ascertainment bias, data from prospective studies are required. Ideally, to accumulate sufficient data in an acceptable time frame, this problem should be tackled in international collaborative efforts combining data from large national registries. Until results from prospective studies become available, retrospective analyses must be considered as the best available basis for clinical decision making.

In summary, there is increasing evidence in the literature that the risks of less common cancers in LS depend on sex and the specific mutated MMR gene. These two factors should be taken

into account for specific cancer surveillance strategies. For instance, *MSH2* mutation carriers may be included in specific surveillance for urothelial and prostate cancer. In Germany, annual upper GI endoscopy is currently recommended for all patients with LS irrespective of the affected MMR gene. However, this advice could possibly be restricted to patients with *MLH1* or *MSH2* mutations, as the risk for gastric or small bowel cancer is considerably lower in patients with *MSH6* mutations.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: Hans K. Schackert, GWT of TU Dresden (C); Heike Goergens, GWT of TU Dresden (C) **Consultant or Advisory Role:** Hans K. Schackert, Medical Care Unit GmbH of the University Hospital Dresden (C); Heike Goergens, Medical Care Unit of the University Hospital Dresden (C); Wolff Schmiegell, Roche (C), Amgen (C), AstraZeneca (C); Gabriela Moeslein, Bayer HealthCare Pharmaceuticals (C) **Stock Ownership:** None **Honoraria:** Hans K. Schackert, onkovic GmbH, Merck Pharma GmbH; Heike Goergens, onkovic GmbH, Merck Pharma GmbH; Wolff Schmiegell, Merck, Roche, Abbott Laboratories, Amgen, Pfizer, Falk, AstraZeneca **Research Funding:** Wolff Schmiegell, Roche, sanofi-aventis, Pfizer **Expert Testimony:** None **Other Remuneration:** Wolff Schmiegell, Roche, Merck, AstraZeneca

AUTHOR CONTRIBUTIONS

Conception and design: Christoph Engel, Markus Loeffler, Elke Holinski-Feder, Reinhard Buettner, Gabriela Moeslein, Hans F.A. Vasen

Provision of study materials or patients: Wolfgang Dietmaier, Noline Hoogerbrugge, Rolf H. Sijmons, Anja Wagner, Irma Kluijt

Collection and assembly of data: Christoph Engel, Markus Loeffler, Verena Steinke, Nils Rahner, Wolfgang Dietmaier, Hans K. Schackert, Heike Goergens, Magnus von Knebel Doeberitz, Timm O. Goecke, Wolff Schmiegell, Reinhard Buettner, Gabriela Moeslein, Tom G.W. Letteboer, Encarna Gómez García, Frederik J. Hes, Noline Hoogerbrugge, Theo A.M. van Os, Rolf H. Sijmons, Anja Wagner, Irma Kluijt, Peter Propping, Hans F.A. Vasen

Data analysis and interpretation: Christoph Engel, Markus Loeffler, Wolff Schmiegell, Tom G.W. Letteboer, Fred H. Menko, Hans F.A. Vasen

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

1. Vasen HF: Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer). *Aliment Pharmacol Ther* 26:113-126, 2007 (suppl 2)

2. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 81:214-218, 1999

3. Bonadona V, Bonaïti B, Olschwang S, et al: Cancer risks associated with germline mutations in *MLH1*, *MSH2*, and *MSH6* genes in Lynch syndrome. *JAMA* 305:2304-2310, 2011

4. Kastrinos F, Mukherjee B, Tayob N, et al: Risk of pancreatic cancer in families with Lynch syndrome. *JAMA* 302:1790-1795, 2009

5. Grindedal EM, Møller P, Eeles R, et al: Germ-line mutations in mismatch repair genes associated with prostate cancer. *Cancer Epidemiol Biomarkers Prev* 18:2460-2467, 2009

6. Scott RJ, McPhillips M, Meldrum CJ, et al: Hereditary nonpolyposis colorectal cancer in 95 families: Differences and similarities between mutation-positive and mutation-negative kindreds. *Am J Hum Genet* 68:118-127, 2001
7. van der Post RS, Kiemeny LA, Ligtenberg MJ, et al: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. *J Med Genet* 47:464-470, 2010
8. Schulmann K, Engel C, Propping P, et al: Small bowel cancer risk in Lynch syndrome. *Gut* 57:1629-1630, 2008
9. Watson P, Vasen HF, Mecklin JP, et al: The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 123:444-449, 2008
10. Capelle LG, Van Grieken NC, Lingsma HF, et al: Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. *Gastroenterology* 138:487-492, 2010
11. Baglietto L, Lindor NM, Dowty JG, et al: Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst* 102:193-201, 2010
12. Barrow E, Robinson L, Alduaij W, et al: Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: A report of 121 families with proven mutations. *Clin Genet* 75:141-149, 2009
13. Goecke T, Schulmann K, Engel C, et al: Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: A report by the German HNPCC Consortium. *J Clin Oncol* 24:4285-4292, 2006
14. Mangold E, Pagenstecher C, Friedl W, et al: Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. *Int J Cancer* 116:692-702, 2005
15. Vasen HF, den Hartog Jager FC, Menko FH, et al: Screening for hereditary non-polyposis colorectal cancer: A study of 22 kindreds in The Netherlands. *Am J Med* 86:278-281, 1989
16. Vasen HF, Stormorken A, Menko FH, et al: MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer families. *J Clin Oncol* 19:4074-4080, 2001
17. Vasen HF, Mecklin JP, Khan PM, et al: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum* 34:424-425, 1991
18. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 116:1453-1456, 1999
19. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. *J Natl Cancer Inst* 89:1758-1762, 1997
20. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 96:261-268, 2004
21. Carayol J, Khat M, Maccario J, et al: Hereditary non-polyposis colorectal cancer: Current risks of colorectal cancer largely overestimated. *J Med Genet* 39:335-339, 2002
22. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 46:765-781, 2010
23. ten Kate GL, Kleibeuker JH, Nagengast FM, et al: Is surveillance of the small bowel indicated for Lynch syndrome families? *Gut* 56:1198-1201, 2007
24. Diergaarde B, Braam H, Vasen HF, et al: Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol* 5:736-742, 2007
25. Winkels RM, Botma A, Van Duijnhoven FJ, et al: Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. *Gastroenterology* 142:241-247, 2012
26. Botma A, Nagengast FM, Braem MG, et al: Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: The GEOLynch cohort study. *J Clin Oncol* 28:4346-4353, 2010
27. Pande M, Lynch PM, Hopper JL, et al: Smoking and colorectal cancer in Lynch syndrome: Results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. *Clin Cancer Res* 16:1331-1339, 2010
28. Watson P, Ashwathnarayan R, Lynch HT, et al: Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). *Arch Intern Med* 164:2429-2431, 2004
29. Chao EC, Lipkin SM: Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. *Nucleic Acids Res* 34:840-852, 2006

Affiliations

Christoph Engel and Markus Loeffler, University of Leipzig, Leipzig; Verena Steinke and Peter Propping, University of Bonn, Bonn; Nils Rahner and Timm O. Goecke University Hospital, Heinrich-Heine-University, Duesseldorf; Elke Holinski-Feder, Klinikum der Universität München, Center of Medical Genetics, Munich; Wolfgang Dietmaier, University of Regensburg, Regensburg; Hans K. Schackert and Heike Goergens, Technische Universität Dresden, Dresden; Magnus von Knebel Doeberitz, University of Heidelberg, Heidelberg; Wolff Schmigel, Knappschafts Krankenhaus, Ruhr-University Bochum, Bochum; Reinhard Buettner, University Hospital of Cologne, Cologne; Gabriela Moeslein, HELIOS St Josefs-Hospital, Bochum-Linden, Germany; Tom G.W. Letteboer, University Medical Centre Utrecht, Utrecht; Encarna Gómez García, University of Maastricht, Maastricht; Frederik J. Hes and Hans F.A. Vasen, Leiden University Medical Centre, Leiden; Nicoline Hoogerbrugge, Radboud University Nijmegen, Medical Centre, Nijmegen; Fred H. Menko, VU University Medical Centre; Theo A.M. van Os, Academic Medical Center; Irma Kluijdt, Family Cancer Clinic, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam; Rolf H. Sijmons, University of Groningen, University Medical Centre Groningen, Groningen; and Anja Wagner, Erasmus Medical Center, Rotterdam, the Netherlands.